TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01605526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045337
Description: Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles
Study: NCT03464994

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ophthalmological examination
Description: * Refraction~* Best corrected visual acuity~* Intraocular pressure~* Slit lamp examination with vital dye (Oxford grading)~* Tear break-up time (TBUT)~* Schirmer I testing~* Specular (TMS-4 Tomey) and elevation (pentacam Oculus and Orbscan Bausch \& Lomb) corneal videotopographies~* Pachymetry~* Questionnaires: Ocular surface disease index, quality of vision (visual analogic scale), and quality of life (NEI-VFQ25)~* questionnaire about ichthyosis severity~* questionnaire about life quality specifically for patient presenting ichthyosis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ophthalmological examination
Description: * Refraction~* Best corrected visual acuity~* Intraocular pressure~* Slit lamp examination with vital dye (Oxford grading)~* Tear break-up time (TBUT)~* Schirmer I testing~* Specular (TMS-4 Tomey) and elevation (pentacam Oculus and Orbscan Bausch \& Lomb) corneal videotopographies~* Pachymetry~* Questionnaires: Ocular surface disease index, quality of vision (visual analogic scale), and quality of life (NEI-VFQ25)~* questionnaire about ichthyosis severity~* questionnaire about life quality specifically for patient presenting ichthyosis
Study: NCT01841944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pikasol
Description: Pikasol®, 3 capsules (1.8 g EPA+DHA)/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil
Description: Corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid), unchanged and according to the manufacturer
Study: NCT01765322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZILOS-TK IVOS Analyzer
Description: The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)
Study: NCT04270955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization of the Middle Meningeal Artery
Description: Using established endovascular techniques and materials patient will have a diagnostic catheter based angiogram performed on the side(s) of the brain where the subdural hematoma is present. After verifying the vascular anatomy to ensure safety of the procedure the Middle Meningeal Artery will be embolized.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization of the Middle Meningeal Artery
Description: Using established endovascular techniques and materials patient will have a diagnostic catheter based angiogram performed on the side(s) of the brain where the subdural hematoma is present. After verifying the vascular anatomy to ensure safety of the procedure the Middle Meningeal Artery will be embolized.
Study: NCT01560000

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary fiber
Description: Wheat, barley, oat and bran fibers added to a breakfast product
Study: NCT03332602

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: free FeSO4
Description: Testmeal with free FeSO4
Study: NCT01964820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Skills Training
Description: Our intervention teaches 8 skills that research suggests lead to increased positive emotions, beginning with basic skills (recognizing and savoring positive events), and progressing to more complex ones such as goal- setting and acts of kindness. Established skills such as reappraising negative thoughts are also taught, in the context of cultivating positive emotions and coping with stress.~The skills are taught over 5 weeks, with one or more new skills introduced each week. A week consists of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting.~For a full description, see A positive affect intervention for people experiencing health-related stress: development and non-randomized pilot test (Moskowitz et al., 2012).
Study: NCT04270955

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care including possible surgical evacuation of subdural hematoma
Description: Standard of care could include observation or intervention including surgical drainage of subdural hematoma by bedside drain, Subdural Evacuating Port System (SEPS), burr hole or craniotomy
Study: NCT03332602

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: free FeSO4 and empty microspheres
Description: Testmeal with free FeSO4 and empty micropsheres

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: free FeSO4 and hylauronic acid
Description: Testmeal with free FeSO4 and hyaluronic acid
Study: NCT04285619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive expectation
Description: After heating, the physiotherapist will apply the bandage with flossing on both ankles, using 2 Voodoo Floss Bands (Power Guidance model). The distal to proximal bandage will begin with a tension of 50-70% and each lap of the bandage will cover 50% of the previous lap. There will be 3 figures of 8 that will cover the hindfoot and the distal third of the leg.~With the bandage applied on both feet, the runners will perform plantar flexion and active dorsal flexion movements in a range of complete joint movement with both ankles, at a constant rate of 2 seconds of plantar flexion, followed by another 2 of dorsal flexion, during A period of 2 minutes. Next, the therapist will remove the bandages and the athlete will walk barefoot for a minute, to restore normal blood flow.~During the first application of the bandage, the investigator will induce the positive expectation through a standardized phrase for all subjects
Study: NCT03332602

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: free FeSO4 and eudragit polymer
Description: Testmeal with free FeSO4 and eudragit polymer

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated FeSO4 3.2%
Description: Testmeal with encapsulated FeSO4 with 3.2% Fe loading

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated FeSO4 20%
Description: Testmeal with encapsulated FeSO4 with 20% Fe loading

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated FeSO4 3.2%, encapsulated Vitamin A
Description: Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A
Study: NCT04285619

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral expectation
Description: After heating, the physiotherapist will apply the bandage with flossing on both ankles, using 2 Voodoo Floss Bands (Power Guidance model). The distal to proximal bandage will begin with a tension of 50-70% and each lap of the bandage will cover 50% of the previous lap. There will be 3 figures of 8 that will cover the hindfoot and the distal third of the leg.~With the bandage applied on both feet, the runners will perform plantar flexion and active dorsal flexion movements in a range of complete joint movement with both ankles, at a constant rate of 2 seconds of plantar flexion, followed by another 2 of dorsal flexion, during A period of 2 minutes. Next, the therapist will remove the bandages and the athlete will walk barefoot for a minute, to restore normal blood flow.~During the first application of the bandage, the researcher will not induce any expectations to the athletes.
Study: NCT03332602

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated FeSO4 3.2%, encapsulated Vitamin A, free Folic Acid
Description: Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A, with free folic acid.
Study: NCT04270955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care including possible surgical evacuation of subdural hematoma
Description: Standard of care could include observation or intervention including surgical drainage of subdural hematoma by bedside drain, Subdural Evacuating Port System (SEPS), burr hole or craniotomy
Study: NCT03332602

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FeSO4 embedded in Hyaluronic acid
Description: Testmeal with FeSO4 embedded in Hyaluronic acid
Study: NCT02125227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin, Metformin, YH14755
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin, Metformin, YH14755
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14755
Description: single dose
Study: NCT02125227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14755
Description: single dose
Study: NCT01798589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethylenediamine dihydrochloride allergen patch
Description: 1 allergen panel containing 2 allergen and 2 control patches
Study: NCT00582140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP with rhGM-CSF
Description: pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP with rhGM-CSF
Description: pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
Study: NCT01915836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web-based video game (Quit IT)
Study: NCT00582140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP with rhGM-CSF
Description: pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
Study: NCT03239366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BioK+ 100% probiotic
Description: The active BioK+ product will include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product will NOT include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
Study: NCT01553630

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIA bone graft
Description: Acute autogenous bone grafting with RIA graft at the time of surgical fixation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery without bone graft
Description: Plating of fracture without bone graft
Study: NCT04043546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic+resistance exercise training program
Description: Personalized exercise program based on the inclusion testing and patient screening will be provided to the patient. The program will consist of a gradual walking program as well as a gradual resistance training program using therabands.
Study: NCT04870242

Intervention type: OTHER
Intervention: Observational study, non-interventional
Description: observational study for the ERAS protocols in pediatric surgery
Study: NCT02372474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell
Description: Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
Study: NCT01682135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV.
Study: NCT02530528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG
Description: Varied application times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG
Description: Varied application times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG
Description: Varied application times

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHG
Description: Varied application times
Study: NCT03729674

Intervention type: DRUG
Intervention: Biosimilar
Description: Biologic-naïve patients starting any biosimilar; patients switching to biosimilar from an alternative biologic therapy; or patients switching to a biosimilar after successfully completing and exiting a previous course of therapy with the equivalent originator drug.

Intervention type: DRUG
Intervention: Originator (legacy) drug
Description: Biologic-naïve patients starting any originator (legacy) drug; patients switching to an originator drug from an alternative biologic therapy; or patients starting a new cycle with the originator drug.
Study: NCT02474433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol (Cytotec)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol (Cytotec)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol (Cytotec)
Study: NCT01705600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Verbalization Repression Rules
Description: The involved subjects will be randomized to either a bracelet with receive verbal repression guidelines OR just a bracelet. They will receive typical physical therapy interventions for the treatment of low back pain (modalities, exercise, manual treatment) with the only change being the education of the one group to repress verblization of pain complaints. The bracelet is worn as a reminder of the rules given.
Study: NCT01617460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Flexibly dose administered orally once daily
Study: NCT03053297

Intervention type: OTHER
Intervention: Patient Reported Outcomes
Description: HRQoL will be assessed using questionnaire EORTC QLQ-C30 and the questionnaire EORTC QLQ-LC 13.~These two questionnaires are validated instruments, translated in various languages and are not used as an intervention but rather to track patient quality of life and symptom reduction in real-life settings. Data for these patient reported outcomes will be collected prospectively from the time of enrolment until the end of follow-up. The two questionnaires will be self-administered by the patients in both cohorts at the enrolment visit and subsequently every 3 months (±1 month) at routine standard of care scheduled visits. The questionnaires are expected to take about 15 minutes to complete

Intervention type: OTHER
Intervention: Patient Reported Outcomes
Description: HRQoL will be assessed using questionnaire EORTC QLQ-C30 and the questionnaire EORTC QLQ-LC 13.~These two questionnaires are validated instruments, translated in various languages and are not used as an intervention but rather to track patient quality of life and symptom reduction in real-life settings. Data for these patient reported outcomes will be collected prospectively from the time of enrolment until the end of follow-up. The two questionnaires will be self-administered by the patients in both cohorts at the enrolment visit and subsequently every 3 months (±1 month) at routine standard of care scheduled visits. The questionnaires are expected to take about 15 minutes to complete
Study: NCT04359303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic indirect endovenous ozone therapy
Description: 200 mL at 40 mcg/mL of medical ozone / oxygen in 200 mL of patients blood mixed in an homologated device for the procedure.
Study: NCT03854708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 pmol/kg*min pancreatic polypeptide
Description: PP 3 pmol/kg\*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 pmol/kg*min pancreatic polypeptide
Description: PP 10 pmol/kg\*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (saline solution) was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. The placebo consists of a 0.9 % saline solution containing 5 % albumin.
Study: NCT04392518

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Breathing, posture, dynamic core stabilization, upper and lower extremity strengthening exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Breathing, posture, dynamic core stabilization, upper and lower extremity strengthening exercises.
Study: NCT01055158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based CBT
Description: A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes. All sessions begin with a depression rating and agenda setting and end with task assignments and summaries.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants randomized to this condition will be referred to receive in-person psychotherapy. Research study staff will help participants to set up their first appointment with a psychotherapist.
Study: NCT03610061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (cohort 6 only)
Description: Cohort 6 patients (only) will receive:~Day 8-Day 10: External Beam Radiotherapy to target site(s)- daily (ie. 5 further fractions to a total of 10 fractions)
Study: NCT03956095

Intervention type: DIETARY_SUPPLEMENT
Intervention: Ensure Surgery Immunonutrition Shake supplements
Description: Three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.

Intervention type: OTHER
Intervention: Daily Food Intake form
Description: On the day of surgery, the patient will return her Daily Supplement/Food Intake Forms and complete the Day of Surgery Intake Form can also be completed the day before surgery and the Daily Supplement/Food Intake Forms can be returned at the patient's postoperative appointment.
Study: NCT05618665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma Education
Description: Asthma education about asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma Education
Description: Asthma education about asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivery of booklets
Description: The booklets, prepared by the researchers, included information about the content of the education.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivery of booklets
Description: The booklets, prepared by the researchers, included information about the content of the education.
Study: NCT01915836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation Interview
Study: NCT04594590

Intervention type: GENETIC
Intervention: Mutation analysis
Description: The investigators will sequence DNA samples from the patients or their families.
Study: NCT03171220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Reactive T Cells(NRTs)
Description: Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 200mg will be administered as an intravenous infusion over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine(FLU) 30mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2(IL-2)will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.
Study: NCT03620786

Intervention type: DEVICE
Intervention: Sonablate HIFU device
Description: In this study, we will be using the Sonablate 450 HIFU System. The Sonablate HIFU device was approved by the U.S. FDA for prostate tissue ablation in October, 2015. HIFU is an example of focal therapy, where the intervention involves targeting diseased areas of prostate tissue, while preserving healthy prostate tissue and minimizing damage to surrounding structures.
Study: NCT04009733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A study specific blood sample will be collected.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A study specific blood sample will be collected.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Pre-collected serum of cohort OFELY and MODAM for women, STRAMBO for men will be used for the study.